The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press3510.17650/1818-8338-2013-1-4-8EDITORIALРЕДАКЦИОННАЯ СТАТЬЯPLACENTAL GROWTH FACTOR AND CORONARY NEOANGIOGENESIS IN CORONARY HEART DISEASEПЛАЦЕНТАРНЫЙ ФАКТОР РОСТА И КОРОНАРНЫЙ НЕОАНГИОГЕНЕЗ ПРИ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦАTulikovM. V.ТуликовМ. В.
Russian Federation
tulikov-mikhail@yandex.ruShevchenkoO. P.ШевченкоО. П.
Russian Federation

Department of Cardiology

кафедра кардиологии факультета усовершенствования врачей

ShevchenkoA. O.ШевченкоА. О.
Russian Federation

Department of Cardiology

кафедра кардиологии факультета усовершенствования врачей

GagayevA. V.ГагаевА. В.
Russian Federation
PavlovV. V.ПавловВ. В.
Russian Federation
Clinical Hospital, Department for Presidential Affairs of the Russian FederationФГБУ «Клиническая больница» Управления делами Президента Российской ФедерацииFaculty for Postgraduate Training of Physicians, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России1501201371481507201415072014Copyright ©; 2013, Tulikov M.V., Shevchenko O.P., Shevchenko A.O., Gagayev A.V., Pavlov V.V.Copyright ©; 2013, Туликов М.В., Шевченко О.П., Шевченко А.О., Гагаев А.В., Павлов В.В.2013Tulikov M.V., Shevchenko O.P., Shevchenko A.O., Gagayev A.V., Pavlov V.V.Туликов М.В., Шевченко О.П., Шевченко А.О., Гагаев А.В., Павлов В.В.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/35

Neoangiogenesis in coronary heart disease is a protective reaction aimed to improve ischemic myocardial perfusion, by increasing the number and size of arterial collaterals. Placental growth factor (PlGF) is one of the key peptides regulating angiogenic processes in atherosclerosis. In particular, a number of investigators have shown that injection of recombinant PlGF into the system or regional blood flow can stimulate neoangiogenesis. On the other hand, there is evidence confirming the involvement of PlGF in the progression of atherosclerosis and in the development of acute coronary syndrome. In this connection, the problem of investigating the efficiency and safety of possible use of PlGF preparations, as well as its place in the diagnosis of coronary heart disease and acute coronary syndrome remains urgent

Неоангиогенез при ишемической болезни сердца является защитной реакцией, направленной на улучшение перфузии ишемизированного миокарда за счет увеличения количества и размера артериальных коллатералей. Одним из ключевых пептидов, регулирующих процессы ангиогенеза при атеросклерозе, является плацентарный фактор роста (PlGF). В частности, рядом исследователей показано, что введение препаратов рекомбинантного PlGF в системный или регионарный кровоток может стимулировать неоангиогенез. С другой стороны, существуют данные, подтверждающие участие PlGF в прогрессировании атеросклероза и развитии острого коронарного синдрома. В связи с этим актуальной остается проблема изучения эффективности и безопасности возможного терапевтического применения препаратов PlGF, а также его места в диагностике ишемической болезни сердца и острого коронарного синдрома.

placental growth factorcoronary heart diseaseacute coronary syndromeprognosisinflammationneoangiogenesisплацентарный фактор ростаишемическая болезнь сердцаострый коронарный синдромпрогнозвоспалениенеоангиогенез1. Felmeden D.C., Blann A.D., Lip G.Y. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003;24(7):586–603.Felmeden D.C., Blann A.D., Lip G.Y. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003;24(7):586–603.2. Apple F.S., Wu A.H., Mair J. et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51(5):810–24.Apple F.S., Wu A.H., Mair J. et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51(5):810–24.3. Gerber H.P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or inGerber H.P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or incombination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65(3):671–80.4. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008;11(3):215–21.Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008;11(3):215–21.5. Selvaraj S., Giri R., Perelman N. et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003;102(4):1515–24.Selvaraj S., Giri R., Perelman N. et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003;102(4):1515–24.6. Fam N.P., Verma S., Kutryk M., Stewart D.J. Clinician guide to angiogenesis. Circulation 2003;108(21):2613–8.Fam N.P., Verma S., Kutryk M., Stewart D.J. Clinician guide to angiogenesis. Circulation 2003;108(21):2613–8.7. Takeda Y., Uemura S., Iwama H. et al. Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J 2009;73(9):1674–82.Takeda Y., Uemura S., Iwama H. et al. Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J 2009;73(9):1674–82.8. Liu X., Caluwe E. Placental growth factor increases regional myocardial blood flow and function in a new porcine model of chronic myocardial ischemia. Circulation 2009;120:S837.Liu X., Caluwe E. Placental growth factor increases regional myocardial blood flow and function in a new porcine model of chronic myocardial ischemia. Circulation 2009;120:S837.9. Nutu O., Molinie V., Shen M. et al. Therapeutic role of placenta growth factor in post-infarct myocardial revascularization. Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_172.Nutu O., Molinie V., Shen M. et al. Therapeutic role of placenta growth factor in post-infarct myocardial revascularization. Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_172.10. Koester W. Endareritis and arteritis. Berl Klin Wschr 1876;13:454–5.Koester W. Endareritis and arteritis. Berl Klin Wschr 1876;13:454–5.11. O'Brien E.R., Garvin M.R., Dev R. el al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145(4):883–94.O'Brien E.R., Garvin M.R., Dev R. el al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145(4):883–94.12. Moreno P.R., Purushothaman K.R., Fuster V. el al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110(14):2032–8.Moreno P.R., Purushothaman K.R., Fuster V. el al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110(14):2032–8.13. Pipp F., Heil M., Issbrücker K. et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003;92(4):378–85.Pipp F., Heil M., Issbrücker K. et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003;92(4):378–85.14. Moulton K.S., Vakili K., Zurakowski D. et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100(8):4736–41.Moulton K.S., Vakili K., Zurakowski D. et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100(8):4736–41.15. Luttun A., Tjwa M., Moons L. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8(8):831–40.Luttun A., Tjwa M., Moons L. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8(8):831–40.16. Khurana R., Moons L., Shafi S. et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005;111(21):2828–36.Khurana R., Moons L., Shafi S. et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005;111(21):2828–36.17. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349(9063):1429–35.The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349(9063):1429–35.18. Heeschen C., Dimmeler S., Fichtlscherer S. et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291(4):435–441.Heeschen C., Dimmeler S., Fichtlscherer S. et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291(4):435–441.19. Шевченко О.П., Шевченко А.О., Орлов а О.В., Туликов М.В. Неоангиогенез и коронарный атеросклероз: диагностическое значение нового биохимического маркера – плацентарного фактора роста P1GF – у больных ишемической болезнью сердца. Кардиология 2006;(11):9–15.Шевченко О.П., Шевченко А.О., Орлов а О.В., Туликов М.В. Неоангиогенез и коронарный атеросклероз: диагностическое значение нового биохимического маркера – плацентарного фактора роста P1GF – у больных ишемической болезнью сердца. Кардиология 2006;(11):9–15.20. Cassidy A., Chiuve S.E., Manson J.E. et al. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009;29(1):134–9.Cassidy A., Chiuve S.E., Manson J.E. et al. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009;29(1):134–9.